Download PDF
Semin Thromb Hemost 2023; 49(08): 816-832
DOI: 10.1055/s-0042-1757634
Review Article

COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment

Luis Ortega-Paz
1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida
,
Azita H. Talasaz
2   Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
,
Parham Sadeghipour
3   Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
4   Clinical Trial Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
,
Tatjana S. Potpara
5   School of Medicine, University of Belgrade, Belgrade, Serbia
6   Intensive Arrhythmia Care, Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia
,
Herbert D. Aronow
7   Department of Cardiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island
8   Department of Cardiology, Henry Ford Health, Detroit, Michigan
,
Luis Jara-Palomares
9   Respiratory Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain
10   Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Carlos III Health Institute, Madrid, Spain
,
Michelle Sholzberg
11   Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
12   Department of Medicine, University of Toronto, Toronto, Ontario, Canada
13   Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
,
Dominick J. Angiolillo
1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida
,
Gregory Y.H. Lip
14   Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
15   Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
,
Behnood Bikdeli
16   Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts
17   Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
18   Yale/YNHH Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut
19   Cardiovascular Research Foundation (CRF), New York, New York
› Author Affiliations Funding No specific funding was sought for this manuscript. L.O-P. was supported by a grant from the Spanish Society of Cardiology (SEC/MHE-MOV-INT 20/001). B.B. is supported by the Scott Schoen and Nancy Adams IGNITE Award from the Mary Horrigan Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital and a Career Development Award from the American Heart Association and VIVA Physicians (#938814) and the Heart and Vascular Center Award from Brigham and Women's Hospital.
› Further Information
   Permissions and Reprints

Abstract

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an excess in thrombotic events, in particular venous thromboembolism. Pulmonary embolism (PE) has been of special interest in patients with COVID-19 given its association with respiratory deterioration, increased risk of intensive care unit admission, and prolonged hospital stay. The pathophysiology and clinical characteristics of COVID-19-associated PE may differ from the conventional non–COVID-19-associated PE. In addition to embolic events from deep vein thrombi, in situ pulmonary thrombosis, particularly in smaller vascular beds, may be relevant in patients with COVID-19. Appropriate prevention of thrombotic events in COVID-19 has therefore become of critical interest. Several changes in viral biology, vaccination, and treatment management during the pandemic may have resulted in changes in incidence trends. This review provides an overview of the pathophysiology, epidemiology, clinical characteristics, and risk factors of COVID-19-associated PE. Furthermore, we briefly summarize the results from randomized controlled trials of preventive antithrombotic therapies in COVID-19, focusing on their findings related to PE. We discuss the acute treatment of COVID-19-associated PE, which is substantially similar to the management of conventional non-COVID-19 PE. Ultimately, we comment on the current knowledge gaps in the evidence and the future directions in the treatment and follow-up of COVID-19-associated PE, including long-term management, and its possible association with long-COVID.

Keywords

SARS-CoV-2 - coronavirus disease 2019 - long COVID - pulmonary embolism - venous thromboembolism - anticoagulant therapy


Publication History

Article published online:
12 October 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc 2021; 10 (03) e019650
    CrossrefPubMedGoogle Scholar
  • 2 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 3 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Gerotziafas GT, Catalano M, Theodorou Y. et al; Scientific Reviewer Committee. The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper. Thromb Haemost 2021; 121 (08) 992-1007
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
    CrossrefPubMedGoogle Scholar
  • 9 Arévalos V, Ortega-Paz L, Rodríguez-Arias JJ. et al. Myocardial injury in COVID-19 patients: association with inflammation, coagulopathy and in-hospital prognosis. J Clin Med 2021; 10 (10) 2096
    CrossrefPubMedGoogle Scholar
  • 10 Poredos P, Poredos P. Involvement of inflammation in venous thromboembolic disease: an update in the age of COVID-19. Semin Thromb Hemost 2022; 48 (01) 93-99
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Arévalos V, Ortega-Paz L, Rodríguez-Arias JJ. et al. Acute and chronic effects of COVID-19 on the cardiovascular system. J Cardiovasc Dev Dis 2021; 8 (10) 128
    CrossrefPubMedGoogle Scholar
  • 13 Talasaz AH, Sadeghipour P, Kakavand H. et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review. J Am Coll Cardiol 2021; 77 (15) 1903-1921
    CrossrefPubMedGoogle Scholar
  • 14 Elalamy I, Gerotziafas G, Alamowitch S. et al; Scientific Reviewer Committee. SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia. Thromb Haemost 2021; 121 (08) 982-991
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 2020; 383 (02) 120-128
    CrossrefPubMedGoogle Scholar
  • 16 Carsana L, Sonzogni A, Nasr A. et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020; 20 (10) 1135-1140
    CrossrefPubMedGoogle Scholar
  • 17 Cohen SL, Gianos E, Barish MA. et al; Northwell Health COVID-19 Research Consortium. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost 2021; 121 (08) 1043-1053
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Cangemi R, Calvieri C, Falcone M. et al. Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicenter observational study. Thromb Haemost 2022; 122 (02) 257-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2 (07) e437-e445
    CrossrefPubMedGoogle Scholar
  • 20 Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41 (32) 3038-3044
    CrossrefPubMedGoogle Scholar
  • 21 Panigada M, Bottino N, Tagliabue P. et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18 (07) 1738-1742
    CrossrefPubMedGoogle Scholar
  • 22 Pellicori P, Doolub G, Wong CM. et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev 2021; 3: CD013879
    PubMedGoogle Scholar
  • 23 Jiménez D, García-Sanchez A, Rali P. et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2021; 159 (03) 1182-1196
    CrossrefPubMedGoogle Scholar
  • 24 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
    CrossrefPubMedGoogle Scholar
  • 25 Fares Y, Sinzogan-Eyoum YC, Billoir P. et al. Systematic screening for a proximal DVT in COVID-19 hospitalized patients: results of a comparative study. J Med Vasc 2021; 46 (04) 163-170
    PubMedGoogle Scholar
  • 26 Lapébie FX, Minville V, Ribes A. et al. Systematic screening for deep vein thrombosis in critically ill inpatients with COVID-19: impact on the incidence of venous thromboembolism. Front Med (Lausanne) 2021; 7: 624808
    CrossrefPubMedGoogle Scholar
  • 27 Ortega-Paz L, Galli M, Capodanno D. et al. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021; pvab070
    PubMedGoogle Scholar
  • 28 Ortega-Paz L, Galli M, Angiolillo DJ. Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19. Eur Heart J Cardiovasc Pharmacother 2022; 8 (03) E15-E17
    CrossrefPubMedGoogle Scholar
  • 29 Cohen CT, Riedl RA, Gowda ST, Sartain SE, Bashir DA. Pulmonary embolism in pediatric and adolescent patients with COVID-19 infection during the SARS-CoV-2 delta wave. Pediatr Blood Cancer 2022; 69 (08) e29721
    CrossrefPubMedGoogle Scholar
  • 30 Law N, Chan J, Kelly C, Auffermann WF, Dunn DP. Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, delta, omicron variants and vaccines. Emerg Radiol 2022; 29 (04) 625-629
    CrossrefPubMedGoogle Scholar
  • 31 Katsoularis I, Fonseca-Rodríguez O, Farrington P. et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study. BMJ 2022; 377: e069590
    CrossrefPubMedGoogle Scholar
  • 32 Kaptein FHJ, Stals MAM, Grootenboers M. et al; Dutch COVID & Thrombosis Coalition. Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thromb Res 2021; 199: 143-148
    CrossrefPubMedGoogle Scholar
  • 33 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 34 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 35 Sakr Y, Giovini M, Leone M. et al. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Ann Intensive Care 2020; 10: 124
    CrossrefPubMedGoogle Scholar
  • 36 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
    CrossrefPubMedGoogle Scholar
  • 37 Fauvel C, Weizman O, Trimaille A. et al; Critical COVID-19 France Investigators. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J 2020; 41 (32) 3058-3068
    CrossrefPubMedGoogle Scholar
  • 38 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 39 Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020; 324 (08) 799-801
    CrossrefPubMedGoogle Scholar
  • 40 Zuin M, Engelen MM, Barco S. et al. Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis. Thromb Res 2022; 209: 94-98
    CrossrefPubMedGoogle Scholar
  • 41 Connors JM, Brooks MM, Sciurba FC. et al; ACTIV-4B Investigators. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326 (17) 1703-1712
    CrossrefPubMedGoogle Scholar
  • 42 Ananworanich J, Mogg R, Dunne MW. et al. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin Infect Dis 2022; 75 (01) e473-e481
    CrossrefPubMedGoogle Scholar
  • 43 Wang L, Chen F, Bai L, Yi Q, Peng Y. In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist. Thromb Res 2020; 196: 541-542
    CrossrefPubMedGoogle Scholar
  • 44 Miró Ò, Jiménez S, Mebazaa A. et al; Spanish Investigators on Emergency Situations TeAm (SIESTA) network. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021; 42 (33) 3127-3142
    CrossrefPubMedGoogle Scholar
  • 45 Bikdeli B, Jimenez D, Hawkins M. et al; RIETE Investigators. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Fernández-Capitán C, Barba R, Díaz-Pedroche MDC. et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021; 47 (04) 351-361
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Suh YJ, Hong H, Ohana M. et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 2021; 298 (02) E70-E80
    CrossrefPubMedGoogle Scholar
  • 48 Buso G, Mazzolai L, Rueda-Camino JA. et al; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023; 49 (01) 34-46
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Talasaz AH, Sadeghipour P, Aghakouchakzadeh M. et al. Use of novel antithrombotic agents for COVID-19: systematic summary of ongoing randomized controlled trials. J Thromb Haemost 2021; 19 (12) 3080-3089
    CrossrefPubMedGoogle Scholar
  • 50 van Dam LF, Kroft LJM, van der Wal LI. et al. Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease?. Thromb Res 2020; 193: 86-89
    CrossrefPubMedGoogle Scholar
  • 51 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 173 (04) 268-277
    CrossrefPubMedGoogle Scholar
  • 52 Bellou V, Tzoulaki I, van Smeden M, Moons KGM, Evangelou E, Belbasis L. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J 2022; 59 (02) 2002964
    CrossrefPubMedGoogle Scholar
  • 53 Harrison SL, Buckley BJR, Rivera-Caravaca JM, Zhang J, Lip GYH. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. Eur Heart J Qual Care Clin Outcomes 2021; 7 (04) 330-339
    PubMedGoogle Scholar
  • 54 Update to living systematic review on prediction models for diagnosis and prognosis of COVID-19. BMJ 2021; 372 (236) n236
    PubMedGoogle Scholar
  • 55 Knight SR, Ho A, Pius R. et al; ISARIC4C Investigators. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 2020; 370: m3339
    CrossrefPubMedGoogle Scholar
  • 56 Knight SR, Gupta RK, Ho A. et al; ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators; ISARIC4C Investigators. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax 2022; 77 (06) 606-615
    CrossrefPubMedGoogle Scholar
  • 57 Gómez CA, Sun CK, Tsai IT. et al. Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis. Sci Rep 2021; 11 (01) 16025
    CrossrefPubMedGoogle Scholar
  • 58 Miró Ò, Jiménez S, Llorens P. et al; SIESTA and PEPCOV Research Teams. Pulmonary embolism severity and in-hospital mortality: an international comparative study between COVID-19 and non-COVID patients. Eur J Intern Med 2022; 98: 69-76
    CrossrefPubMedGoogle Scholar
  • 59 Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine 2020; 29: 100639
    CrossrefPubMedGoogle Scholar
  • 60 Roberts LN, Navaratnam AV, Arya R, Briggs TWR, Gray WK. Venous thromboembolism in patients hospitalised with COVID-19 in England. Thromb Res 2022; 213: 138-144
    CrossrefPubMedGoogle Scholar
  • 61 Driggin E, Madhavan MV, Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020; 75 (18) 2352-2371
    CrossrefPubMedGoogle Scholar
  • 62 Rizk JG, Gupta A, Lazo Jr JG. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023; 49 (01) 62-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Tritschler T, Mathieu ME, Skeith L. et al; International Network of VENous Thromboembolism Clinical Research Networks INVENT-VTE. Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost 2020; 18 (11) 2958-2967
    CrossrefPubMedGoogle Scholar
  • 64 Flumignan RL, Tinôco JDS, Pascoal PI. et al. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev 2020; 10: CD013739
    PubMedGoogle Scholar
  • 65 Janiaud P, Hemkens LG, Ioannidis JPA. Challenges and lessons learned from COVID-19 trials: Should we be doing clinical trials differently?. Can J Cardiol 2021; 37 (09) 1353-1364
    CrossrefPubMedGoogle Scholar
  • 66 Sholzberg M, da Costa BR, Tang GH. et al; RAPID Trial Investigators. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost 2021; 5 (08) e12638
    CrossrefPubMedGoogle Scholar
  • 67 Bikdeli B, Chatterjee S, Kirtane AJ. et al. Sulodexide versus control and the risk of thrombotic and hemorrhagic events: meta-analysis of randomized trials. Semin Thromb Hemost 2020; 46 (08) 908-918
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost 2021; 121 (07) 944-954
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Cools F, Virdone S, Sawhney J. et al; ETHIC Investigators. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol 2022; 9 (08) e594-e604
    CrossrefPubMedGoogle Scholar
  • 70 Barco S, Voci D, Held U. et al; OVID Investigators. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol 2022; 9 (08) e585-e593
    CrossrefPubMedGoogle Scholar
  • 71 Capell WH, Barnathan ES, Piazza G. et al. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: the PREVENT-HD study. Am Heart J 2021; 235: 12-23
    CrossrefPubMedGoogle Scholar
  • 72 Lopes RD, de Barros E Silva PGM, Furtado RHM. et al; ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397 (10291): 2253-2263
    CrossrefPubMedGoogle Scholar
  • 73 Marcos-Jubilar M, Carmona-Torre F, Vidal R. et al; BEMICOP Investigators. Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP Study): an open-label, multicenter, randomized, controlled trial. Thromb Haemost 2022; 122 (02) 295-299
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Sholzberg M, Tang GH, Rahhal H. et al; RAPID Trial Investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375 (2400): n2400
    CrossrefPubMedGoogle Scholar
  • 75 Morici N, Podda G, Birocchi S. et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 Randomized Trial. Eur J Clin Invest 2022; 52 (05) e13735
    CrossrefPubMedGoogle Scholar
  • 76 Lawler PR, Goligher EC, Berger JS. et al; ATTACC Investigators; ACTIV-4A Investigators; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 790-802
    CrossrefPubMedGoogle Scholar
  • 77 Spyropoulos AC, Goldin M, Giannis D. et al; HEP-COVID Investigators. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021; 181 (12) 1612-1620
    CrossrefPubMedGoogle Scholar
  • 78 Farkouh ME, Stone GW, Lala A. et al. Anticoagulation in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol 2022; 79 (09) 917-928
    CrossrefPubMedGoogle Scholar
  • 79 Lemos ACB, do Espírito Santo DA, Salvetti MC. et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359-366
    CrossrefPubMedGoogle Scholar
  • 80 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION Randomized Trial. Thromb Haemost 2022; 122 (01) 131-141
    Article in Thieme ConnectPubMedGoogle Scholar
  • 81 Sadeghipour P, Talasaz AH, Rashidi F. et al; INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial. JAMA 2021; 325 (16) 1620-1630
    CrossrefPubMedGoogle Scholar
  • 82 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19 (09) 2225-2234
    CrossrefPubMedGoogle Scholar
  • 83 Blondon M, Cereghetti S, Pugin J. et al. Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial. Res Pract Thromb Haemost 2022; 6 (04) e12712
    CrossrefPubMedGoogle Scholar
  • 84 Goligher EC, Bradbury CA, McVerry BJ. et al; REMAP-CAP Investigators; ACTIV-4A Investigators; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med 2021; 385 (09) 777-789
    CrossrefPubMedGoogle Scholar
  • 85 Ramacciotti E, Barile Agati L, Calderaro D. et al; MICHELLE Investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399 (10319): 50-59
    CrossrefPubMedGoogle Scholar
  • 86 Group RC. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022; 399 (10320): 143-151
    CrossrefPubMedGoogle Scholar
  • 87 Bradbury CA, Lawler PR, Stanworth SJ. et al; REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2022; 327 (13) 1247-1259
    CrossrefPubMedGoogle Scholar
  • 88 Horby PW, Emberson JR, Mafham M. et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medRxiv 2022; 2022.2003.2002.22271623
    PubMedGoogle Scholar
  • 89 RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med 2021; 9 (12) 1419-1426
    CrossrefPubMedGoogle Scholar
  • 90 INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with COVID-19 in intensive care: randomized controlled trial. BMJ 2022; 376: e068407
    PubMedGoogle Scholar
  • 91 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020; 383 (19) 1813-1826
    CrossrefPubMedGoogle Scholar
  • 92 Caricchio R, Abbate A, Gordeev I. et al; CAN-COVID Investigators. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA 2021; 326 (03) 230-239
    CrossrefPubMedGoogle Scholar
  • 93 COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed July 15, 2020 at: https://www.covid19treatmentguidelines.nih.gov/
    PubMedGoogle Scholar
  • 94 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (03) 872-888
    CrossrefPubMedGoogle Scholar
  • 95 Moores LK, Tritschler T, Brosnahan S. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest 2022; 162 (01) 213-225
    CrossrefPubMedGoogle Scholar
  • 96 Schulman S, Sholzberg M, Spyropoulos AC. et al; International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2022; 20 (10) 2214-2225
    CrossrefPubMedGoogle Scholar
  • 97 Goldin M, Lin SK, Kohn N. et al. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombolysis 2021; 52 (04) 1032-1035
    CrossrefPubMedGoogle Scholar
  • 98 Mouhat B, Besutti M, Bouiller K. et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J 2020; 56 (04) 2001811
    CrossrefPubMedGoogle Scholar
  • 99 Ooi MWX, Rajai A, Patel R, Gerova N, Godhamgaonkar V, Liong SY. Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography - prevalence, pattern of disease and relationship to D-dimer. Eur J Radiol 2020; 132: 109336
    CrossrefPubMedGoogle Scholar
  • 100 Martens ESL, Huisman MV, Klok FA. Diagnostic management of acute pulmonary embolism in COVID-19 and other special patient populations. Diagnostics (Basel) 2022; 12 (06) 1350
    CrossrefPubMedGoogle Scholar
  • 101 Rindi LV, Al Moghazi S, Donno DR, Cataldo MA, Petrosillo N. Predictive scores for the diagnosis of pulmonary embolism in COVID-19: a systematic review. Int J Infect Dis 2022; 115: 93-100
    CrossrefPubMedGoogle Scholar
  • 102 García-Ortega A, Oscullo G, Calvillo P. et al. Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. J Infect 2021; 82 (02) 261-269
    CrossrefPubMedGoogle Scholar
  • 103 Rosovsky RP, Grodzin C, Channick R. et al; PERT Consortium. Diagnosis and treatment of pulmonary embolism during the coronavirus disease 2019 pandemic: a position paper from the National PERT Consortium. Chest 2020; 158 (06) 2590-2601
    CrossrefPubMedGoogle Scholar
  • 104 Philippe J, Cordeanu EM, Leimbach MB, Greciano S, Younes W. Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: a case series of seven patients admitted to a regional hospital in the French epidemic cluster. Eur Heart J Case Rep 2021; 5 (02) ytaa522
    CrossrefPubMedGoogle Scholar
  • 105 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 106 Rashidi F, Barco S, Rezaeifar P. et al. Tissue plasminogen activator for the treatment of adults with critical COVID-19: a pilot randomized clinical trial. Thromb Res 2022; 216: 125-128
    CrossrefPubMedGoogle Scholar
  • 107 Delrue M, Stépanian A, Voicu S. et al. No VTE recurrence after 1-year follow-up of hospitalized patients with COVID-19 and a VTE event: a prospective study. Chest 2022; 162 (01) 226-229
    CrossrefPubMedGoogle Scholar
  • 108 Wolter N, Jassat W, Walaza S. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399 (10323): 437-446
    CrossrefPubMedGoogle Scholar
  • 109 Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022; 114: 252-260
    CrossrefPubMedGoogle Scholar
  • 110 Pottegård A, Lund LC, Karlstad Ø. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 2021; 373 (1114): n1114
    CrossrefPubMedGoogle Scholar
  • 111 Xie J, Prats-Uribe A, Feng Q. et al. Venous thromboembolism in ambulatory COVID-19 patients: clinical and genetic determinants. medRxiv 2022:2022.2003.2022.22272748
    PubMedGoogle Scholar
  • 112 Tung ML, Tan B, Cherian R, Chandra B. Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol Adv Pract 2021; 5 (01) rkaa081
    CrossrefPubMedGoogle Scholar
  • 113 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Kakkos S, Kirkilesis G, Caprini JA. et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev 2022; 1: CD005258
    PubMedGoogle Scholar
  • 115 Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit Care 2020; 24 (01) 559
    CrossrefPubMedGoogle Scholar
  • 116 CANVECTOR. COVID-19 VTE-Related Rapid Response Funding Competition. Accessed July 15, 2020 at: https://www.canvector.ca/research/anticoagulation-in-hospitalized-patients-with-covid-19
    PubMedGoogle Scholar
  • 117 Swayngim R, Preslaski C, Burlew CC, Beyer J. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis. Thromb Res 2021; 208: 18-25
    CrossrefPubMedGoogle Scholar
  • 118 Manson L, Weitz JI, Podor TJ, Hirsh J, Young E. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. J Lab Clin Med 1997; 130 (06) 649-655
    CrossrefPubMedGoogle Scholar
  • 119 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397 (10285): 1637-1645
    CrossrefPubMedGoogle Scholar
  • 120 Guimarães PO, Quirk D, Furtado RH. et al; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med 2021; 385 (05) 406-415
    CrossrefPubMedGoogle Scholar
  • 121 Horby P, Lim WS, Emberson JR. et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021; 384 (08) 693-704
    CrossrefPubMedGoogle Scholar
  • 122 Gordon AC, Mouncey PR, Al-Beidh F. et al; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 2021; 384 (16) 1491-1502
    CrossrefPubMedGoogle Scholar
  • 123 Qanadli SD, Gudmundsson L, Rotzinger DC. Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: thinking beyond the guidelines. Thromb Res 2020; 192: 9-11
    CrossrefPubMedGoogle Scholar
  • 124 Klok FA, Piazza G, Sharp ASP. et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study. Am Heart J 2022; 251: 43-53
    CrossrefPubMedGoogle Scholar
  • 125 Arevalos V, Ortega-Paz L, Brugaletta S. Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes. Med Clin (Barc) 2022; 158 (01) 41-42
    CrossrefPubMedGoogle Scholar
  • 126 Arévalos V, Ortega-Paz L, Fernandez-Rodríguez D. et al; CV COVID-19 Registry Investigators. Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: a structured summary of a study protocol. PLoS One 2021; 16 (07) e0255263
    CrossrefPubMedGoogle Scholar
  • 127 Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28 (03) 583-590
    CrossrefPubMedGoogle Scholar
  • 128 Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22 (04) e102-e107
    CrossrefPubMedGoogle Scholar
  • 129 Morin L, Savale L, Pham T. et al; Writing Committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021; 325 (15) 1525-1534
    CrossrefPubMedGoogle Scholar
  • 130 Heesakkers H, van der Hoeven JG, Corsten S. et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA 2022; 327 (06) 559-565
    CrossrefPubMedGoogle Scholar
  • 131 Newman J, Boubriak I, Jenkins D. et al. Rising COVID-19 related acute pulmonary emboli but falling national chronic thromboembolic pulmonary hypertension referrals from a large national dataset. ERJ Open Res 2021; 7 (04) 00431-02021
    CrossrefPubMedGoogle Scholar
  • 132 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) 2247-2259
    CrossrefPubMedGoogle Scholar